Protein Kinase Inhibitors: all 15,041 studies that test it

Page 86 of 151. Open to participants first (2,484), then studies with results posted, then the rest; newest registration first within each.

• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
• Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
• Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentStatus unknownNCT04882345Phase 2
• SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
• A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With OmeprazoleCompletedNCT04876807Phase 1
• A Phase II Trial of Cabozantinib With Patients With Refractory GCTsCompletedNCT04876456Phase 2
• Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenibCompletedNCT04874207Phase 4
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)TerminatedNCT04873895Phase 1
• Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingNCT04872985Phase 2
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
• Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownNCT04870190Phase 3
• Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
• A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult ParticipantsCompletedNCT04867980Phase 1
• A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1
• Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant RecipientsStatus unknownNCT04867720Phase 4
• An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
• A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04866134Phase 1/2
• A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous ChemotherapyStatus unknownNCT04866108Phase 2
• Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the StomachWithdrawnNCT04863430Phase 2
• A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionStatus unknownNCT04863365Phase 3
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
• The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or ParagangliomaCompletedNCT04860700Phase 2
• Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingNCT04859946Phase 2
• Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsStatus unknownNCT04858997Phase 2
• Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion MutationCompletedNCT04858958Phase 1
• Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerWithdrawnNCT04856475Phase 2
• Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)CompletedNCT04856293Phase 1
• Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaStatus unknownNCT04856111Phase 4
• A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CancerActive, not recruitingNCT04854668Phase 3
• Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04851613Phase 3
• Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaActive, not recruitingNCT04850495Phase 1
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT04849715Phase 3
• Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)Status unknownNCT04849533Phase 4
• Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
• Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult SubjectsCompletedNCT04843540Phase 1
• Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT04843098Phase 1/2
• Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeActive, not recruitingNCT04842617Phase 3
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLStatus unknownNCT04842370Phase 1
• MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)Active, not recruitingNCT04841811Phase 3
• Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2
• BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedNCT04839471Phase 2
• Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell TransplantationCompletedNCT04838704Not applicable
• Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
• Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
• A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic TumorsStatus unknownNCT04836663Phase 2
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1
• Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid ArthritisCompletedNCT04834557Phase 2
• A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaCompletedNCT04833582Phase 1
• 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaWithdrawnNCT04832438Phase 2
• Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver MetastasesStatus unknownNCT04832204Phase 2
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.CompletedNCT04831996Phase 1
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.CompletedNCT04831944Phase 1
• Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerCompletedNCT04830813Phase 3
• Dasatinib for the Treatment of Moderate and Severe COVID-19WithdrawnNCT04830735Phase 2
• Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following KeloidectomyCompletedNCT04827875Phase 1
• Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaWithdrawnNCT04827589Phase 2
• A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)CompletedNCT04827069Phase 1
• A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2
• A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsCompletedNCT04826341Phase 1/2
• Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory OsteosarcomaSuspendedNCT04824352Phase 2
• Keynatinib in Treated Patients with NSCLC and Brain MetastasesCompletedNCT04824079Phase 2
• A Study of Anlotinib in the Treatment of Recurrent High-grade GliomaStatus unknownNCT04822805Phase 2
• Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive VitiligoCompletedNCT04822584Phase 2
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Phase 3
• AZD9833 China PK StudyCompletedNCT04818632Phase 1
• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)TerminatedNCT04816604Phase 2
• The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult ManCompletedNCT04816123Phase 1
• Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic CancerStatus unknownNCT04814485Phase 2
• A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompletedNCT04814108Phase 2
• To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionStatus unknownNCT04814056Phase 4
• Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04813406Not applicable
• Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerStatus unknownNCT04809142Phase 3
• Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain MetastasesActive, not recruitingNCT04808752Phase 2
• A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04808570Phase 1/2
• Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib CreamCompletedNCT04807751Phase 1
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2
• A Pharmacokinetic Study of TQB3101 in Chinese Healthy SubjectsCompletedNCT04804904Phase 1
• Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
• SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2
• Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic CancerStatus unknownNCT04803851Phase 1/2
• Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALLTerminatedNCT04803123Early Phase 1
• Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT04802590Phase 2
• Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersActive, not recruitingNCT04802174Phase 1/2
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• A Study to Explore the Effect of Food Before a Single Dose of SitravatinibCompletedNCT04800614Phase 1
• Tofacitinib as a GC Sparing Agent for Polymyalgia RheumaticaCompletedNCT04799262Phase 2
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT04799249Phase 3
• A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompletedNCT04798638Phase 1
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCStatus unknownNCT04797806Phase 3
• SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell CancerStatus unknownNCT04797507Phase 2
• To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)WithdrawnNCT04796922Phase 3
• A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerCompletedNCT04796623Phase 2
• Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2

← Protein Kinase Inhibitors overview